Juno Therapeutics Raises $134 Million for Series B Round


Seattle-based Juno Therapeutics Inc., a biotechnology company focusing on novel immunotherapies for cancer, closed a Series B round with US$ 134 million in new investment. In total, Juno has raised over US$ 300 million in the past 12 months – this includes a US$ 176 million Series A round in April. The new capital will be used to continue advancing Juno’s chimeric antigen receptor and T-cell receptor pipeline. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute

institutional investor investment mandates